Prominent publications by Antoni Ribas

KOL Index score: 23574

BACKGROUND: The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF(V600)-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated efficacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.

METHODS: In this double-blind, randomised, placebo-controlled, multicentre study, ...

Also Ranks for: Cobimetinib Vemurafenib |  male melanoma |  cobrim study |  months 95 |  braf v600
KOL Index score: 23158

BACKGROUND: Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma.

METHODS: We carried out a randomised phase 2 trial of patients aged 18 years or older from 73 hospitals, clinics, and academic medical centres in 12 countries who had confirmed ...

Also Ranks for: Patients Pembrolizumab |  2 trial |  choice chemotherapy |  treatment ipilimumab |  progressionfree survival
KOL Index score: 20881

BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis.

METHODS: In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, ...

Also Ranks for: Advanced Melanoma |  3 study |  pembrolizumab ipilimumab |  humanized antineoplastic agents |  antibodies monoclonal
KOL Index score: 19815

BACKGROUND: Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between body-mass index (BMI) and progression-free survival or overall survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.

METHODS: This retrospective study analysed independent cohorts of patients with ...

Also Ranks for: Metastatic Melanoma |  patients bmi |  obesity survival |  antineoplastic agents |  targeted therapy immunotherapy
KOL Index score: 19596

BACKGROUND: Addition of a MEK inhibitor to a BRAF inhibitor enhances tumour growth inhibition, delays acquired resistance, and abrogates paradoxical activation of the MAPK pathway in preclinical models of BRAF-mutated melanoma. We assessed the safety and efficacy of combined BRAF inhibition with vemurafenib and MEK inhibition with cobimetinib in patients with advanced BRAF-mutated melanoma.

METHODS: We undertook a phase 1b study in patients with advanced BRAF(V600)-mutated melanoma. We ...

Also Ranks for: Vemurafenib Cobimetinib |  braf inhibitor |  mutated melanoma |  drug combination |  grade 3
KOL Index score: 19368

BACKGROUND: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progress using MEK inhibitors following disease progression in patients receiving BRAF inhibitors. However, the PI3K/AKT pathway can also induce resistance to the inhibitors of MAPK pathway.


Also Ranks for: Mek Inhibitors |  mtor pathway |  tumor drug resistance |  protein kinase |  melanoma cell
KOL Index score: 18751

BACKGROUND: Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting. However, the optimal duration of anti-PD-1 administration is unknown. We present results from 5 years of follow-up of patients in KEYNOTE-006.

METHODS: KEYNOTE-006 was an open-label, multicentre, randomised, controlled, phase 3 study done at 87 academic institutions, hospitals, and cancer centres in ...

Also Ranks for: Advanced Melanoma |  pembrolizumab patients |  5 years |  ipilimumab 3 |  efficacy safety
KOL Index score: 18737

BACKGROUND: Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab.

METHODS: In this open-label, phase 1b trial, we recruited patients from 12 medical centres in Australia, New Zealand, and the USA. Eligible patients were aged ...

Also Ranks for: Dose Pembrolizumab |  advanced melanoma |  monoclonal antibodies |  ipilimumab patients |  objective response
KOL Index score: 18340

BACKGROUND: In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone. Here, we present the effects of treatments on health-related quality of life (HRQoL), an exploratory endpoint in the COMBI-v study.

METHODS: COMBI-v was an open-label, randomised ...

Also Ranks for: Combination Therapy |  dabrafenib trametinib |  progression disease |  primary endpoint |  phase 3
KOL Index score: 18126

Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients.

Patients and methods: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant ...

Also Ranks for: Dabrafenib Trametinib |  mutant melanoma |  3 study |  braf v600e |  monotherapy patients
KOL Index score: 16895

BACKGROUND: In the BRIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and progression in patients with advanced BRAF(V600) mutation-positive melanoma. We present an extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF(V600K) mutation subgroups.

METHODS: Patients older than 18 years, with treatment-naive metastatic melanoma and whose tumour tissue was positive for BRAF(V600) mutations were eligible. Patients also ...

Also Ranks for: Vemurafenib Dacarbazine |  braf v600 |  positive melanoma |  months 95 |  median progressionfree survival
KOL Index score: 16864

BACKGROUND: Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAFV600E-mutant or BRAFV600K-mutant advanced melanoma; however, in many patients the disease progresses, leading to death. With many treatment options available, understanding clinical factors that predict long-term response and survival for treatments is important for optimisation of patient management. We aimed to identify clinical factors associated with ...

Also Ranks for: Randomised Trials |  pooled analysis |  survival progression |  dabrafenib trametinib |  individual patient
KOL Index score: 16639

Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability of responses with immunotherapy. However, the first clinical trial testing the combination of the BRAF inhibitor vemurafenib and the CTLA4 antibody ipilimumab was terminated early because of substantial liver toxicities. MEK [MAPK (mitogen-activated protein kinase) kinase] inhibitors can potentiate the MAPK inhibition in BRAF ...

Also Ranks for: Mek Inhibitors |  antitumor activity |  dabrafenib trametinib |  immunotherapy braf |  antigen cell
KOL Index score: 16135

BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune response in brain tumor patients have met with limited success, which is due to brain immune privilege, tumor immune evasion, and a paucity of dendritic cells (DCs) within the central nervous system. Herein we uncovered a novel pathway for the activation of an effective anti-GBM immune response mediated by ...

Also Ranks for: Tumor Cells |  tlr2 activation |  therapeutic efficacy |  endogenous ligand |  brain immune
KOL Index score: 15906

IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.

OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma.

DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study ...

Also Ranks for: Advanced Melanoma |  tumor response |  monoclonal antibodies |  rate treatment |  measurable disease

Key People For Advanced Melanoma

Top KOLs in the world
Dirk ***********
melanoma patients advisory consultancy braf v600
Caroline ******
advanced melanoma braf v600 advisory consultancy
Frank ******* ****
advanced melanoma brain metastases nivolumab ipilimumab
Reinhard * ******
metastatic melanoma cutaneous lymphomas advisory consultancy
Jean ******* ****
advisory consultancy advanced melanoma grant funding
Jeffrey * *****
metastatic melanoma advisory consultancy complete resection

Antoni Ribas:Expert Impact

Concepts for whichAntoni Ribashas direct influence:Advanced melanoma,  Metastatic melanoma,  Dendritic cells,  Braf v600,  Cobimetinib vemurafenib,  Monoclonal antibodies.

Antoni Ribas:KOL impact

Concepts related to the work of other authors for whichfor which Antoni Ribas has influence:Cancer immunotherapy,  Immune checkpoint inhibitors,  Metastatic melanoma,  Tumor microenvironment,  Hepatocellular carcinoma,  Dendritic cells,  Cell death.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Division of Hematology and Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA | Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA | Parker Institute for Cancer Immunotherapy, San Fra